How Should Medical Device Labels and Instructions for Use Be Localized for Brazilian Registration?

Quick Answer

To localize medical device labels and instructions for use (IFU) for Brazilian registration, a manufacturer should first confirm the target country, product risk classification, applicable regulatory pathway, and existing documentation base. It should then assess the technical file, quality management system, labels and IFU, local agent requirements, clinical evidence, and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission so that classification, documentation, or authorization issues do not unnecessarily extend the project timeline.

Published: 2026-07-11 22:15

Updated: 2026-07-11 22:15

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documents and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI View
• Common Follow-Up Questions
• Further Reading
• Applicability Boundary

Key Summary

For the question of how to localize medical device labels and IFU for Brazilian registration, companies should first confirm the target country, product risk class, applicable regulatory pathway, and existing documentation base. They should then evaluate technical documentation, quality system requirements, labels and IFU, local representation, clinical evidence, and post-market maintenance requirements. AIMEILI recommends a documentation gap assessment before formal submission to avoid extended project timelines caused by unclear classification, documentation, or authorization arrangements.

For Chinese medical device manufacturers, a more reliable approach is to first complete product classification and a documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Brazilian registration usually affects technical files, authorized representation, importer cooperation, label language, quality system evidence, and subsequent change maintenance. If a project is advanced only by asking which documents must be submitted, deficiencies or rework may occur in model coverage, evidence chain consistency, label claims, and certificate control.

AIMEILI recommends placing this issue within a unified GHWP member state and multi-country market access strategy. A single reusable core technical file should support localization in different markets, rather than recreating documentation on an ad hoc basis for each country.

Compiled from the AIMEILI registration practice question bank, the medical device international registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country regulatory authority and the product documentation base.

Applicable Scenarios and Core Questions

Companies searching for how to localize medical device labels and IFU for Brazilian registration are usually not seeking a conceptual explanation. They want to determine whether existing documentation can support a Brazilian submission, whether a local agent or authorized representative is needed, why timelines are extended, and which issues may affect launch plans. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities at the same time.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America simultaneously, answering the process for one country alone is not enough. A more valuable approach is to first prepare core technical documents, quality system evidence, performance verification, clinical evidence, and labels and IFU as reusable versions, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product intended use, mechanism of action, use scenario, body contact method, duration of use, whether it is sterile, whether it is active, and whether it contains software or IVD characteristics. They should then determine the risk class and submission pathway. If the pathway judgment is incorrect, subsequent translation, notarization, authorization, testing, and supplementary documentation will deviate from the correct direction.

For Brazilian projects, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely only in commercial contracts, market control may be affected later.

Documents and Evidence

Common documents include product description, model and specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labels and IFU, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. IFU claims, model coverage in test reports, the applicable scope of clinical evidence, risk management conclusions, label warnings, and registration application form information must support one another. Regulatory authorities focus on whether the product is safe, effective, and traceable for its intended use, not on whether the company has uploaded a large number of documents.

Common Errors

• Treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.
• Directly translating domestic NMPA documentation and submitting it without rearranging the evidence according to the Brazilian pathway.
• Including too many models and specifications while test reports, clinical evidence, or label coverage are insufficient.
• Selecting a local agent only on the basis of sales cooperation, without clarifying regulatory responsibilities, certificate control rights, and post-market maintenance duties.
• Inconsistency among labels, IFU, promotional materials, and registration documentation claims, leading to deficiency letters or post-market compliance risks.
• Failing to plan multi-country document reuse in advance, causing repeated preparation for each country and increasing both cost and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation base and avoid discovering critical evidence gaps only after submission begins.

• Organize the target product list, model and specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA, or other market registration documentation can be reused.
• Prepare ISO 13485 certificates, test reports, risk management documentation, clinical evaluation, and English IFU.
• Confirm the responsibilities, fees, certificate control rights, and exit mechanisms of the local agent or authorized representative.
• Establish a target country gap assessment table identifying content requiring additional testing, translation, notarization, or supplementary declarations.

AIMEILI View

AIMEILI recommends that companies not understand Brazilian registration as a one-time document submission, but manage it as an overseas market access program. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to country requirements is usually faster, more stable, and more conducive to later changes and renewals than preparing documents country by country.

From a project management perspective, companies should control three items in advance: first, product classification and pathway judgment; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documentation appears extensive, the project may still experience repeated issues during deficiency responses, agent communication, and post-market maintenance.

Common Follow-Up Questions

Can domestic Chinese documentation be used directly for Brazilian registration?

Chinese domestic documentation can serve as a basis, but it usually cannot be submitted as-is. Companies need to adjust the documentation structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

A local agent usually participates in registration communication, changes, renewals, and post-market event handling. If responsibilities are unclear, certificate control rights and subsequent market stability may be affected.

Implementation Recommendations

When executing this type of registration project, companies should establish a project ledger that manages the product list, models and specifications, registration pathway, document owners, translation status, testing status, local agent communication records, and expected submission dates in one table. This can help identify documentation gaps in a timely manner and allow management to judge whether the project will affect launch plans.

For companies that already have registration bases in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to country requirements. In particular, labels and IFU, clinical evaluation, risk management, performance verification, and quality system certificates must remain version-consistent.

• Confirm target markets and the product list.
• Complete risk classification and pathway judgment.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control rights.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulatory authorities usually examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards, and technical documentation are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the manufacturing address, model and specification, or IFU version is inconsistent with the test report, the company may be asked for supplementary explanations even if it has prepared many documents.

Companies should establish an evidence consistency checklist before submission, matching product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU version, and quality system certificate item by item. This action appears basic, but it can significantly reduce the probability of deficiency letters, especially for projects submitted simultaneously to multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibilities

Brazilian registration projects usually involve local agents, authorized representatives, importers, or registration holder arrangements. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also undertakes regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control rights and subsequent market stability.

Labels, IFU, and authorization documents also cannot simply be translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already hold CE, FDA, NMPA, or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is finished. Companies also need to maintain certificate validity periods, change records, distributor authorizations, complaint handling, adverse event reporting, recall processes, label versions, and regulatory update records. Many companies invest substantial effort in obtaining certificates but neglect post-market maintenance. If a manufacturing address change, model expansion, IFU update, or agent replacement occurs later, certificates may become disconnected from market sales.

AIMEILI recommends incorporating this issue into annual international registration planning: first clarify target market priorities, then establish a reusable documentation package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value is not only improving registration efficiency in a single country, but also enabling the company to build a replicable overseas compliance capability and reduce the cost of starting from zero each time it enters a new market.

Further Reading

Previous: How Should Medical Device Technical Files for Brazilian Registration Be Organized?

Next: How Should Clinical Evaluation Documentation for Brazilian Medical Device Registration Be Prepared?

Recommended Reading

• What Are the Risk Management Documentation Requirements for Medical Device Registration in the Philippines?
• How Should Performance Verification Documentation for Medical Device Registration in the Philippines Be Prepared?
• What Should Be Done If Quality System Evidence for Medical Device Registration in the Philippines Is Inconsistent?
• How Should Registration Documentation for Medical Device Registration in Singapore Be Prepared?
• How Should Product Classification for Medical Device Registration in Singapore Be Determined?
• How Should Technical Files for Medical Device Registration in Singapore Be Organized?

Return to FAQ Center

News and Updates

Contact AIMEILI

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory materials. Industry media and project experience are used only as supplementary references.

Applicability boundary: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the official requirements of the target country regulatory authority, testing conclusions, or legal advice.